23:13 , Jan 24, 2018 |  BC Extra  |  Company News

Management tracks: Ablynx, Cardiovascular Systems

Nanobody company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) hired Robert Friesen as CSO, effective March 1. He is SVP of science and early development at ProQR Therapeutics N.V. (NASDAQ:PRQR). Medical device company Cardiovascular Systems Inc. (NASDAQ:CSII) said...
08:00 , Mar 2, 2009 |  BC Week In Review  |  Company News

Replidyne, Cardiovascular Systems deal

Replidyne and medical device company Cardiovascular Systems completed their previously announced reverse merger (see BioCentury, Nov. 10, 2008). Replidyne Inc. (NASDAQ:RDYN), Louisville, Colo.   Cardiovascular Systems Inc. , St. Paul, Minn.   Business: Cardiovascular  ...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Company News

Replidyne, Cardiovascular Systems deal

Replidyne will reverse-merge into medical device company Cardiovascular Systems. Cardiovascular Systems' stockholders will own 83% of the combined company, and Replidyne shareholders will own the remaining 17%. The deal is expected to close next quarter....
08:00 , Nov 10, 2008 |  BioCentury  |  Finance

Ebb & Flow

In the largest biotech venture financing this year, cancer stem cell antibody company OncoMed received the $93 million final tranche of a B round that totaled $154 million. New investor Nomura Phase4 participated in the...
08:00 , Feb 11, 2008 |  BioCentury  |  Product Development

Too low, too fast?

Contradictory data were reported last week from two similar studies seeking to reduce blood sugar in Type II diabetes patients to levels more like those seen in non-diabetics. In one study, the intensive glycemic arm...
08:00 , Mar 5, 2007 |  BioCentury  |  Tools & Techniques

Predicting active peptides

Compugen Ltd. says it has developed an in silico discovery engine for peptides that bind GPCRs. So far, the engine has yielded eight peptides with dose-dependent activity, and CGEN plans to advance two into preclinical...
07:00 , Jul 31, 2006 |  BioCentury  |  Emerging Company Profile

Tengion: Playing the neo-organ

The demand for donor organs vastly outstrips supply and serious adverse effects are associated with transplantation. As a result, the search for alternatives has ranged from encapsulating cells to generating functioning organs from a patient's...
07:00 , Apr 24, 2006 |  BC Week In Review  |  Company News

Harvest Tech, Terumo Corp. sales and marketing update

Harvest granted Terumo subsidiary Terumo Cardiovascular Systems Corp. (Ann Arbor, Mich.) exclusive U.S. and Canadian rights to distribute SmartPrep2 platelet concentration system for wound healing in the cardiovascular and perfusion markets. Harvest Technologies Corp. ,...
07:00 , Sep 11, 2000 |  BC Extra  |  Top Story

Top tiers in takeovers

M&A activity picked up on Monday with a fury with three top tier biotech companies, Elan (ELN), Genzyme General (GENZ) and Human Genome Sciences (HGSI), announcing deals totaling nearly $3 billion. ELN entered a definitive...
07:00 , May 22, 2000 |  BioCentury  |  Strategy

Beating cheap competition

By Kathryn Calkins Staff writer Amid the increasing uproar over the cost of prescription drugs, companies bringing new treatments to competitive settings need to make a compelling case in order to win market share. And...